Table 1 Baseline Patient Characteristics
|  | Iomab-B Arm (N = 76) | Conventional Care Arm (N = 77) | Randomized to Conventional Care and Crossed Over to Iomab-B (N = 44) |
|---|---|---|---|
Age, years Median (Range) | 64 (55–77) Pts ≥70 yrs: 14 (18.4%) | 66 (55–76) Pts ≥70 yrs: 16 (20.8%) | 64 (55–76) Pts ≥70 yrs: 12 (27.3%) |
Cytogenetic and Molecular Risk* N (%) | Favorable: 5 (6.6) Intermediate: 27 (35.5) Adverse: 43 (56.6) | Favorable: 2 (2.6) Intermediate: 31 (40.3) Adverse: 43 (55.8) | Favorable: 1 (2.3) Intermediate: 21 (47.7) Adverse: 21 (47.7) |
Disease Status at Randomization N (%) | Primary Induction Failure: 43 (56.6) First Early Relapse:16 (21.1) Relapse/Refractory: 10 (13.2) 2nd + Relapse: 7 (9.2) | Primary Induction Failure: 40 (51.9) First Early Relapse: 22 (28.6) Relapse/Refractory: 10 (13.0) 2nd + Relapse: 5 (6.5) | Primary Induction Failure: 24 (54.5) First Early Relapse: 11 (25.0) Relapse/Refractory: 7 (15.9) 2nd + Relapse: 2 (4.5) |
Prior Lines of Treatment Median (Range) | 3 (1–8) | 3 (1–8) | 3 (1-8) |
Received Prior Targeted Therapy N (%) | 47 (61.8) | 47 (61.0) | 26 (59.1) |
Karnofsky Performance Status N (%) | ≥90: 31 (40.8)  < 90: 45 (59.2) | ≥90: 34 (44.2)  < 90: 43 (55.8) | ≥90: 22 (50.0) <90: 22 (50.0) |
% Marrow Blasts at Randomization Median (Range) | 30% (2–97)** | 20% (3–97)** | At Randomization: 24.5% (3–87)** At crossover: 35% (2–89)** |
